Stryker Corp (SYK)

$377.79 -14.94 (-3.80%)
Market Cap 149.90B
Revenue (ttm) 22.60B
Net Income (ttm) 2.99B
EPS (ttm) N/A
PE Ratio 31.96
Forward PE 29.99
Profit Margin 13.25%
Debt to Equity Ratio 0.80
Volume 3,012,300
Avg Vol 1,239,734
Day's Range N/A - N/A
Shares Out 381.69M
Stochastic %K 17%
Beta 0.91
Analysts Strong Sell
Price Target $433.50

Company Profile

Stryker Corporation operates as a medical technology company. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, minimally invasive products for the t...

Industry: Medical Devices
Sector: Healthcare
Phone: (269) 385-2600
Fax: (269) 385-1062
Address:
1941 Stryker Way, Portage, United States
scientificway
scientificway Aug. 2 at 7:39 PM
$SYK check MDXG out, huge guidance
0 · Reply
Investtomakemoney
Investtomakemoney Aug. 2 at 11:48 AM
$SYK If you continue to hold it for 1-2 years, the price will reach more than $500
0 · Reply
OptionRunners
OptionRunners Aug. 1 at 2:23 PM
$SYK Seller of the August 15th $390 puts 2,000+ times for $11. Profit taking from yesterday.
0 · Reply
ZacksResearch
ZacksResearch Aug. 1 at 2:17 PM
$SYK beats Q2 estimates but drops 5.8% after-hours. What gives? 🤔 📈 Adjusted EPS of $3.13 surpassed the Zacks Consensus Estimate of $3.06, with an 11.4% YoY increase. 📊 Revenue hit $6.02B, up 11.1% YoY at constant currency, driven by strong product demand. Despite raising 2025 guidance, market sentiment turned bearish. Full breakdown here 👉 https://www.zacks.com/stock/news/2648692/syk-stock-falls-despite-q2-earnings-sales-beat-25-view-up?cid=sm-stocktwits-2-2648692-body-5314&ADID=SYND_STOCKTWITS_TWEET_2_2648692_BODY_5314
0 · Reply
JarvisFlow
JarvisFlow Aug. 1 at 2:15 PM
Wells Fargo has updated their rating for Stryker ( $SYK ) to Overweight with a price target of 445.
0 · Reply
Chartsgalore
Chartsgalore Aug. 1 at 1:01 PM
$SYK after a strong beat and raise quarter last night, nearly every analyst covering the stock reiterated Buy rating & RAISED their price targets. The stock should be trading higher, not down 7%! Could rally like a bat out of hell once the market opens. $SPY $QQQ
0 · Reply
ChristopherBrecher
ChristopherBrecher Aug. 1 at 12:59 PM
$SYK I only discussed one earnings short trade yesterday, SYK, How did that work out?
0 · Reply
ZacksResearch
ZacksResearch Aug. 1 at 12:19 PM
$SYK beat earnings and raised 2025 guidance — so why is the stock down? Q2 showed strong segment performance and expanding operating margins, yet shares slipped post-report. Full story behind the move here 👉 https://www.zacks.com/stock/news/2648692/syk-stock-falls-despite-q2-earnings-sales-beat-25-view-up?cid=sm-stocktwits-2-2648692-teaser-5296&ADID=SYND_STOCKTWITS_TWEET_2_2648692_TEASER_5296
0 · Reply
JarvisFlow
JarvisFlow Aug. 1 at 10:00 AM
Needham updates rating for Stryker ( $SYK ) to Buy, target set at 442 → 448.
0 · Reply
Chartsgalore
Chartsgalore Aug. 1 at 5:14 AM
$SYK TD Cowen reiterates Buy & $435 PT Upgrade to Premium Stryker’s Strong Financial Performance and Optimistic Outlook Justify Buy Stryker’s Strong Financial Performance and Optimistic Outlook Justify Buy Josh Jennings has given his Buy rating due to a combination of factors, primarily focusing on Stryker’s strong financial performance and optimistic future outlook. The company reported a notable increase in Q2 revenue and earnings per share (EPS), both of which surpassed market expectations. This robust performance was driven by significant organic sales growth, especially in the MedSurg and Neurotechnology segments, which saw an 11% increase. Additionally, the Orthopedics division also showed strong growth, aligning with market forecasts. Stryker’s management has raised its guidance for future organic sales growth and EPS, reflecting confidence in continued operational momentum. The updated guidance suggests an improvement in organic sales growth to 9.5-10% and an increase in EPS
0 · Reply
Latest News on SYK
Stryker Corporation (SYK) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 9:59 PM EDT - 1 day ago

Stryker Corporation (SYK) Q2 2025 Earnings Call Transcript

Stryker raises annual profit forecast on steady demand for surgical devices

Jul 31, 2025, 4:55 PM EDT - 2 days ago

Stryker raises annual profit forecast on steady demand for surgical devices

Stryker reports second quarter 2025 operating results

Jul 31, 2025, 4:05 PM EDT - 2 days ago

Stryker reports second quarter 2025 operating results

10 stocks favored to gain up to 30% in a sector that has missed this year's rally

Jul 31, 2025, 9:52 AM EDT - 2 days ago

10 stocks favored to gain up to 30% in a sector that has missed this year's rally

BSX CAH DXCM EW ISRG LLY PODD

Inari Medical, now part of Stryker, launches the all-new InThrill® Thrombectomy System, designed to address arteriovenous access and small vessel thrombus cases

Jul 29, 2025, 9:07 AM EDT - 4 days ago

Inari Medical, now part of Stryker, launches the all-new InThrill® Thrombectomy System, designed to address arteriovenous access and small vessel thrombus cases

North America Cystoscopes Market Outlook Report 2025-2033 Featuring Key Companies - Olympus, KARL STORZ, Stryker, PENTAX Medical, Richard Wolf, Ambu, Laborie Medical Technologies

Jul 11, 2025, 5:07 AM EDT - 22 days ago

North America Cystoscopes Market Outlook Report 2025-2033 Featuring Key Companies - Olympus, KARL STORZ, Stryker, PENTAX Medical, Richard Wolf, Ambu, Laborie Medical Technologies

Stryker to announce financial results for its second quarter of fiscal year 2025

Jul 1, 2025, 8:00 AM EDT - 4 weeks ago

Stryker to announce financial results for its second quarter of fiscal year 2025

The Big 3: NXT, ANET, SYK

Jun 26, 2025, 1:01 PM EDT - 5 weeks ago

The Big 3: NXT, ANET, SYK

ANET NXT

Stryker receives FDA clearance for Incompass Total Ankle System

Jun 25, 2025, 8:15 AM EDT - 5 weeks ago

Stryker receives FDA clearance for Incompass Total Ankle System

The 3 Most Overvalued Stocks Top Managers Are Selling in 2025

Jun 3, 2025, 11:09 AM EDT - 2 months ago

The 3 Most Overvalued Stocks Top Managers Are Selling in 2025

MA NFLX

Stryker receives FDA clearance for OptaBlate® BVN Basivertebral Nerve Ablation System

May 19, 2025, 1:01 PM EDT - 2 months ago

Stryker receives FDA clearance for OptaBlate® BVN Basivertebral Nerve Ablation System

Baron Opportunity Fund Q1 2025 Top Contributors And Detractors

May 15, 2025, 8:05 AM EDT - 2 months ago

Baron Opportunity Fund Q1 2025 Top Contributors And Detractors

AMZN AVGO CSGP MSFT NVDA SPOT TSLA

Stryker Corporation (SYK) Bank of America Securities 2025 Global Healthcare Conference (Transcript)

May 13, 2025, 8:23 PM EDT - 2 months ago

Stryker Corporation (SYK) Bank of America Securities 2025 Global Healthcare Conference (Transcript)

Stryker: Mako Spine And Shoulder Launching Is On Track (Downgrade To Hold)

May 9, 2025, 5:42 PM EDT - 3 months ago

Stryker: Mako Spine And Shoulder Launching Is On Track (Downgrade To Hold)

Stryker declares an $0.84 per share quarterly dividend

May 8, 2025, 8:00 AM EDT - 3 months ago

Stryker declares an $0.84 per share quarterly dividend

Final Trades: Rockwell Automation, Alerian MLP, Lockheed Martin and Stryker

May 5, 2025, 2:20 PM EDT - 3 months ago

Final Trades: Rockwell Automation, Alerian MLP, Lockheed Martin and Stryker

LMT ROK AMLP

Stryker Corporation (SYK) Q1 2025 Earnings Call Transcript

May 1, 2025, 8:28 PM EDT - 3 months ago

Stryker Corporation (SYK) Q1 2025 Earnings Call Transcript

Stryker beats quarterly estimates of string medical device demand

May 1, 2025, 6:33 PM EDT - 3 months ago

Stryker beats quarterly estimates of string medical device demand

Stryker reports first quarter 2025 operating results

May 1, 2025, 4:05 PM EDT - 3 months ago

Stryker reports first quarter 2025 operating results

Stryker to participate in the Bank of America Securities 2025 Global Healthcare Conference

Apr 29, 2025, 8:00 AM EDT - 3 months ago

Stryker to participate in the Bank of America Securities 2025 Global Healthcare Conference

Viscogliosi Brothers Completes Acquisition of U.S. Spine Business from Stryker, Creating VB Spine, LLC

Apr 1, 2025, 4:26 PM EDT - 4 months ago

Viscogliosi Brothers Completes Acquisition of U.S. Spine Business from Stryker, Creating VB Spine, LLC

Stryker completes sale of U.S. spinal implants business

Apr 1, 2025, 4:05 PM EDT - 4 months ago

Stryker completes sale of U.S. spinal implants business

Stryker announces intention to nominate Manny Maceda to board of directors

Mar 26, 2025, 10:15 AM EDT - 4 months ago

Stryker announces intention to nominate Manny Maceda to board of directors

Stryker announces Annual Meeting of Shareholders

Mar 25, 2025, 4:15 PM EDT - 4 months ago

Stryker announces Annual Meeting of Shareholders

The Big 3: MMM, PM, SYK

Mar 18, 2025, 1:01 PM EDT - 4 months ago

The Big 3: MMM, PM, SYK

MMM PM

Stryker showcases next generation of Mako SmartRobotics™ at AAOS 2025 Annual Meeting

Mar 11, 2025, 8:03 AM EDT - 5 months ago

Stryker showcases next generation of Mako SmartRobotics™ at AAOS 2025 Annual Meeting

Inari Medical, now part of Stryker, launches Artix™ Thrombectomy System, designed to address a broad spectrum of arterial thrombus cases

Mar 6, 2025, 1:36 PM EST - 5 months ago

Inari Medical, now part of Stryker, launches Artix™ Thrombectomy System, designed to address a broad spectrum of arterial thrombus cases

Stryker launches Steri-Shield 8 personal protection system

Mar 4, 2025, 8:07 AM EST - 5 months ago

Stryker launches Steri-Shield 8 personal protection system

Stryker launches Sync Badge

Mar 3, 2025, 8:07 AM EST - 5 months ago

Stryker launches Sync Badge

Stryker Corporation (SYK) Citi's 2025 Unplugged Medtech and Life Sciences Access Day (Transcript)

Feb 28, 2025, 5:24 PM EST - 5 months ago

Stryker Corporation (SYK) Citi's 2025 Unplugged Medtech and Life Sciences Access Day (Transcript)

The Big 3: FTNT, NXT, SYK

Feb 20, 2025, 12:14 PM EST - 5 months ago

The Big 3: FTNT, NXT, SYK

FTNT NXT

Stryker completes acquisition of Inari Medical, Inc., providing entry into the high-growth peripheral vascular segment

Feb 19, 2025, 8:30 AM EST - 5 months ago

Stryker completes acquisition of Inari Medical, Inc., providing entry into the high-growth peripheral vascular segment

Kadant Set to Join S&P SmallCap 600

Feb 13, 2025, 5:54 PM EST - 6 months ago

Kadant Set to Join S&P SmallCap 600

KAI

Stryker to participate in Citi's 2025 Unplugged Medtech and Life Sciences Access Day

Feb 13, 2025, 8:00 AM EST - 6 months ago

Stryker to participate in Citi's 2025 Unplugged Medtech and Life Sciences Access Day

Stryker announces Allan Golston will retire from Board of Directors

Feb 10, 2025, 4:05 PM EST - 6 months ago

Stryker announces Allan Golston will retire from Board of Directors

Sales Growth, Strategic Acquisitions Drive Stryker Higher

Jan 31, 2025, 4:34 PM EST - 6 months ago

Sales Growth, Strategic Acquisitions Drive Stryker Higher

Stryker's Strategic Moves Impress Analysts, Spine Implant Sale and NARI Deal Set to Drive Future Growth

Jan 29, 2025, 1:48 PM EST - 6 months ago

Stryker's Strategic Moves Impress Analysts, Spine Implant Sale and NARI Deal Set to Drive Future Growth

Stryker Corporation (SYK) Q4 2024 Earnings Conference Call Transcript

Jan 28, 2025, 9:34 PM EST - 6 months ago

Stryker Corporation (SYK) Q4 2024 Earnings Conference Call Transcript

Stryker forecasts 2025 profit above estimates on robust demand for surgical devices

Jan 28, 2025, 5:33 PM EST - 6 months ago

Stryker forecasts 2025 profit above estimates on robust demand for surgical devices

Overlooked Stock: SYK

Jan 28, 2025, 4:45 PM EST - 6 months ago

Overlooked Stock: SYK

Stryker reports 2024 operating results and 2025 outlook

Jan 28, 2025, 4:05 PM EST - 6 months ago

Stryker reports 2024 operating results and 2025 outlook

Stryker announces definitive agreement for the sale of its U.S. spinal implants business and plans to sell related international business

Jan 28, 2025, 4:05 PM EST - 6 months ago

Stryker announces definitive agreement for the sale of its U.S. spinal implants business and plans to sell related international business

Stryker announces the retirement of Glenn S. Boehnlein and the promotion of Preston Wells to Vice President, Chief Financial Officer

Jan 28, 2025, 4:05 PM EST - 6 months ago

Stryker announces the retirement of Glenn S. Boehnlein and the promotion of Preston Wells to Vice President, Chief Financial Officer

Stryker: A Cool Name For An Awesome Company, But Is It A Buy Ahead Of Earnings?

Jan 27, 2025, 12:49 PM EST - 6 months ago

Stryker: A Cool Name For An Awesome Company, But Is It A Buy Ahead Of Earnings?

Stryker commences tender offer for all outstanding shares of common stock of Inari Medical, Inc.

Jan 17, 2025, 4:20 PM EST - 7 months ago

Stryker commences tender offer for all outstanding shares of common stock of Inari Medical, Inc.

INARI MEDICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inari Medical, Inc. - NARI

Jan 7, 2025, 6:55 PM EST - 7 months ago

INARI MEDICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inari Medical, Inc. - NARI

Stryker To Buy Inari Medical In $5 Billion Deal To Bolster Venous Thromboembolism Position

Jan 7, 2025, 7:55 AM EST - 7 months ago

Stryker To Buy Inari Medical In $5 Billion Deal To Bolster Venous Thromboembolism Position

Stryker to Acquire Inari Medical in Deal Valued at $4.9 Billion

Jan 6, 2025, 5:19 PM EST - 7 months ago

Stryker to Acquire Inari Medical in Deal Valued at $4.9 Billion

Stryker announces definitive agreement to acquire Inari Medical, Inc., providing entry into high-growth peripheral vascular segment

Jan 6, 2025, 4:08 PM EST - 7 months ago

Stryker announces definitive agreement to acquire Inari Medical, Inc., providing entry into high-growth peripheral vascular segment

Exclusive: Medical device maker Stryker nearing a deal to buy Inari Medical, sources say

Jan 6, 2025, 3:19 PM EST - 7 months ago

Exclusive: Medical device maker Stryker nearing a deal to buy Inari Medical, sources say

scientificway
scientificway Aug. 2 at 7:39 PM
$SYK check MDXG out, huge guidance
0 · Reply
Investtomakemoney
Investtomakemoney Aug. 2 at 11:48 AM
$SYK If you continue to hold it for 1-2 years, the price will reach more than $500
0 · Reply
OptionRunners
OptionRunners Aug. 1 at 2:23 PM
$SYK Seller of the August 15th $390 puts 2,000+ times for $11. Profit taking from yesterday.
0 · Reply
ZacksResearch
ZacksResearch Aug. 1 at 2:17 PM
$SYK beats Q2 estimates but drops 5.8% after-hours. What gives? 🤔 📈 Adjusted EPS of $3.13 surpassed the Zacks Consensus Estimate of $3.06, with an 11.4% YoY increase. 📊 Revenue hit $6.02B, up 11.1% YoY at constant currency, driven by strong product demand. Despite raising 2025 guidance, market sentiment turned bearish. Full breakdown here 👉 https://www.zacks.com/stock/news/2648692/syk-stock-falls-despite-q2-earnings-sales-beat-25-view-up?cid=sm-stocktwits-2-2648692-body-5314&ADID=SYND_STOCKTWITS_TWEET_2_2648692_BODY_5314
0 · Reply
JarvisFlow
JarvisFlow Aug. 1 at 2:15 PM
Wells Fargo has updated their rating for Stryker ( $SYK ) to Overweight with a price target of 445.
0 · Reply
Chartsgalore
Chartsgalore Aug. 1 at 1:01 PM
$SYK after a strong beat and raise quarter last night, nearly every analyst covering the stock reiterated Buy rating & RAISED their price targets. The stock should be trading higher, not down 7%! Could rally like a bat out of hell once the market opens. $SPY $QQQ
0 · Reply
ChristopherBrecher
ChristopherBrecher Aug. 1 at 12:59 PM
$SYK I only discussed one earnings short trade yesterday, SYK, How did that work out?
0 · Reply
ZacksResearch
ZacksResearch Aug. 1 at 12:19 PM
$SYK beat earnings and raised 2025 guidance — so why is the stock down? Q2 showed strong segment performance and expanding operating margins, yet shares slipped post-report. Full story behind the move here 👉 https://www.zacks.com/stock/news/2648692/syk-stock-falls-despite-q2-earnings-sales-beat-25-view-up?cid=sm-stocktwits-2-2648692-teaser-5296&ADID=SYND_STOCKTWITS_TWEET_2_2648692_TEASER_5296
0 · Reply
JarvisFlow
JarvisFlow Aug. 1 at 10:00 AM
Needham updates rating for Stryker ( $SYK ) to Buy, target set at 442 → 448.
0 · Reply
Chartsgalore
Chartsgalore Aug. 1 at 5:14 AM
$SYK TD Cowen reiterates Buy & $435 PT Upgrade to Premium Stryker’s Strong Financial Performance and Optimistic Outlook Justify Buy Stryker’s Strong Financial Performance and Optimistic Outlook Justify Buy Josh Jennings has given his Buy rating due to a combination of factors, primarily focusing on Stryker’s strong financial performance and optimistic future outlook. The company reported a notable increase in Q2 revenue and earnings per share (EPS), both of which surpassed market expectations. This robust performance was driven by significant organic sales growth, especially in the MedSurg and Neurotechnology segments, which saw an 11% increase. Additionally, the Orthopedics division also showed strong growth, aligning with market forecasts. Stryker’s management has raised its guidance for future organic sales growth and EPS, reflecting confidence in continued operational momentum. The updated guidance suggests an improvement in organic sales growth to 9.5-10% and an increase in EPS
0 · Reply
sherowcap
sherowcap Jul. 31 at 11:18 PM
$SYK Best HC co for innovation. Resilient growth portfolio, guess it wasn’t ready to break out this qtr but not going to stay under 400 forever with the growth & profitability combination.
0 · Reply
Chartsgalore
Chartsgalore Jul. 31 at 10:07 PM
$SYK down big on strong earnings and increased outlook, because of tariffs?? This is the 800 lb gorilla of medtech and could be a good buying opp down here $SPY $QQQ
1 · Reply
1986iamwallstreet
1986iamwallstreet Jul. 31 at 9:28 PM
$SYK below 270
1 · Reply
OptionRunners
OptionRunners Jul. 31 at 8:11 PM
$SYK down 3.5% on earnings. Puts closed at $7.85...
1 · Reply
1986iamwallstreet
1986iamwallstreet Jul. 31 at 8:10 PM
$SYK bleeding 🩸
0 · Reply
smartkarma
smartkarma Jul. 31 at 8:08 PM
📈 Earnings Alert $SYK - Stryker 2Q Adj EPS Beats Estimates: ∙ Adj EPS $3.13, est $3.07 ∙ Net sales $6.02b, est $5.94b ∙ MedSurg & Neurotechnology net sales $3.77b, est $3.7b ∙ Instruments net sales $768M, est $763.2m https://www.smartkarma.com/entities/stryker-corp
0 · Reply
OptionRunners
OptionRunners Jul. 31 at 6:11 PM
$SYK puts are almost $7.00 already
0 · Reply
27R
27R Jul. 31 at 4:54 PM
$SYK Earnings release at after closed today, significant post-earnings volatility with relatively reasonable implied volatility, perhaps consider a Straddle
0 · Reply
OptionRunners
OptionRunners Jul. 31 at 4:40 PM
$SYK Buyer of the August 15th $390 puts 2,050 times for $4.80 ahead of earnings tonight
2 · Reply
Estimize
Estimize Jul. 31 at 3:00 PM
$SYK reports after the close, Estimize Consensus +0.03 EPS and +51.23M Revs compared to WS http://www.estimize.com/syk/fq2-2025?utm_content
0 · Reply
NVDAMillionaire
NVDAMillionaire Jul. 30 at 9:38 PM
$SYK Brilliant piece that captures SYK's situation perfectly. So if you want to update your understanding of SYK or get to know SYK better, this is essential reading. https://beyondspx.com/article/stryker-sustaining-high-growth-through-innovation-and-strategic-portfolio-evolution-nyse-syk
0 · Reply
ZacksResearch
ZacksResearch Jul. 29 at 5:05 PM
$SYK Q2 earnings: Will tariff pressures weigh on growth? ⚖️ Stryker's top-line performance likely stayed strong with robust Mako demand and product launches, but initial tariff effects may have impeded Q2 performance, with more impact expected later. 📈 See the full analysis here 👉 https://www.zacks.com/stock/news/2633272/will-syks-q2-earnings-reflect-strong-growth-despite-tariff-overhang?cid=sm-stocktwits-2-2633272-body-4402&ADID=SYND_STOCKTWITS_TWEET_2_2633272_BODY_4402
0 · Reply